InnoCare Pharma Ltd. A vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

InnoCare Pharma Ltd. A (688428.CG)

Q3 202614 Jul – 24 Aug 2026

▲4

InnoCare's pipeline wins and first-half profit mark a turning point

Orelabrutinib Phase 3 data published, confirming best-in-class profile Published Phase 3 results show orelabrutinib cut the risk of CLL/SLL worsening or death by 68% versus older chemo-immunotherapy, with a strong safety profile. It is already approved and reimbursed in China, so this backs up existing sales and makes future growth more believable.
Confirms the core marketed drug's clinical strength, supporting revenue durability.
Two TYK2 inhibitors hit Phase 3 goals in skin diseases Soficitinib met its main goal in a Phase 3 atopic dermatitis trial, and fadeucravacitinib did the same in plaque psoriasis. Both are oral drugs for large, chronic skin conditions, so success widens the company's future revenue beyond its blood-cancer drugs.
Adds two new late-stage assets that could become major future sellers.
Mesutoclax combination gets fast-track status and Phase 3 clearance China's drug regulator gave the orelabrutinib-mesutoclax combo Breakthrough Therapy Designation in lymphoma, and cleared a head-to-head Phase 3 trial of mesutoclax plus azacitidine in newly diagnosed AML. Faster reviews and a pivotal trial shorten the path to new approvals.
Regulatory acceleration de-risks and speeds up a key next-generation pipeline drug.
First-half 2026 results show 55.5% revenue growth and a profit Revenue rose 55.5% to RMB 1.1 billion and the company swung to a RMB 239.7 million profit, helped by orelabrutinib and new launches. With about RMB 8.4 billion in cash, it can fund its pipeline without needing to raise money soon.
The profit turnaround and cash pile are the clearest sign the business is now self-funding.

August 202614 Jul – 24 Aug 2026

▲4

InnoCare's pipeline wins and first-half profit mark a turning point

Orelabrutinib Phase 3 data published, confirming best-in-class profile Published Phase 3 results show orelabrutinib cut the risk of CLL/SLL worsening or death by 68% versus older chemo-immunotherapy, with a strong safety profile. It is already approved and reimbursed in China, so this backs up existing sales and makes future growth more believable.
Confirms the core marketed drug's clinical strength, supporting revenue durability.
Two TYK2 inhibitors hit Phase 3 goals in skin diseases Soficitinib met its main goal in a Phase 3 atopic dermatitis trial, and fadeucravacitinib did the same in plaque psoriasis. Both are oral drugs for large, chronic skin conditions, so success widens the company's future revenue beyond its blood-cancer drugs.
Adds two new late-stage assets that could become major future sellers.
Mesutoclax combination gets fast-track status and Phase 3 clearance China's drug regulator gave the orelabrutinib-mesutoclax combo Breakthrough Therapy Designation in lymphoma, and cleared a head-to-head Phase 3 trial of mesutoclax plus azacitidine in newly diagnosed AML. Faster reviews and a pivotal trial shorten the path to new approvals.
Regulatory acceleration de-risks and speeds up a key next-generation pipeline drug.
First-half 2026 results show 55.5% revenue growth and a profit Revenue rose 55.5% to RMB 1.1 billion and the company swung to a RMB 239.7 million profit, helped by orelabrutinib and new launches. With about RMB 8.4 billion in cash, it can fund its pipeline without needing to raise money soon.
The profit turnaround and cash pile are the clearest sign the business is now self-funding.

Latest14 Jul – 24 Aug 2026

▲4

InnoCare's pipeline wins and first-half profit mark a turning point

Orelabrutinib Phase 3 data published, confirming best-in-class profile Published Phase 3 results show orelabrutinib cut the risk of CLL/SLL worsening or death by 68% versus older chemo-immunotherapy, with a strong safety profile. It is already approved and reimbursed in China, so this backs up existing sales and makes future growth more believable.
Confirms the core marketed drug's clinical strength, supporting revenue durability.
Two TYK2 inhibitors hit Phase 3 goals in skin diseases Soficitinib met its main goal in a Phase 3 atopic dermatitis trial, and fadeucravacitinib did the same in plaque psoriasis. Both are oral drugs for large, chronic skin conditions, so success widens the company's future revenue beyond its blood-cancer drugs.
Adds two new late-stage assets that could become major future sellers.
Mesutoclax combination gets fast-track status and Phase 3 clearance China's drug regulator gave the orelabrutinib-mesutoclax combo Breakthrough Therapy Designation in lymphoma, and cleared a head-to-head Phase 3 trial of mesutoclax plus azacitidine in newly diagnosed AML. Faster reviews and a pivotal trial shorten the path to new approvals.
Regulatory acceleration de-risks and speeds up a key next-generation pipeline drug.
First-half 2026 results show 55.5% revenue growth and a profit Revenue rose 55.5% to RMB 1.1 billion and the company swung to a RMB 239.7 million profit, helped by orelabrutinib and new launches. With about RMB 8.4 billion in cash, it can fund its pipeline without needing to raise money soon.
The profit turnaround and cash pile are the clearest sign the business is now self-funding.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.